Apoptosis regulatory pathways – indirect modulation, no direct binding

Apoptosis regulatory pathways – indirect modulation, no direct binding refers to the pharmacological induction of programmed cell death through the disruption of cellular processes upstream of the core apoptotic machinery. Unlike direct modulators such as BH3 mimetics (e.g., Venetoclax), these agents do not bind to BCL-2 family proteins or caspases; instead, they trigger apoptosis by inducing DNA damage, proteotoxic stress, or by inhibiting essential survival kinases (NIH, 2023; PubMed, 2021). For example, proteasome inhibitors like Bortezomib lead to the accumulation of misfolded proteins, which eventually activates the intrinsic apoptotic pathway via the unfolded protein response (StatPearls, 2023). Similarly, tyrosine kinase inhibitors like Imatinib deprive cells of growth signals, indirectly shifting the balance toward pro-apoptotic signaling (NCBI, 2022). This term is a functional classification used to describe drugs that achieve a pro-apoptotic outcome as a secondary effect of their primary molecular interaction. Consequently, it is not a discrete molecular target but a description of a therapeutic mechanism.

Other names

Indirect apoptosis inductionNon-direct apoptotic modulationUpstream apoptotic signaling disruption

Indirect induction of apoptosis via cellular stress, DNA damage, or inhibition of pro-survival signaling pathways.